FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
The FDA approved Otarmeni (lunsotogene parvec-cwha), which represents the first dual adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of genetic hearing loss.
Manufacturers of AAV-based gene therapies, sponsors utilizing dual-vector delivery systems, and clinical teams specialized in otolaryngology and genetic disorders.
The approval marks a technical milestone in gene therapy by utilizing a dual-vector system, which may suggest a pathway for delivering larger genetic payloads that exceed the capacity of a single AAV vector. The use of a National Priority Voucher suggests the FDA prioritized this review, indicating a regulatory emphasis on unmet needs in sensory genetic conditions. Regulatory teams should note this as a precedent for the approval of multi-vector biologics.
Regulatory and CMC teams should evaluate the technical requirements for dual AAV vector systems. Clinical operations should prepare for specialized administration protocols associated with inner ear gene delivery. Post-market teams should anticipate long-term follow-up requirements typical of novel gene therapy platforms.
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.
Open in openFDA / FDA.gov